From 867c1e47061934d048d9a287fb9f521ed0cc44c3 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 16 Mar 2026 14:49:20 +0000 Subject: [PATCH] extract: 2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk Pentagon-Agent: Ganymede --- ...t cost impact inflationary through 2035.md | 6 +++++ ...ients-undermining-chronic-use-economics.md | 6 +++++ ...copenia-glp1-muscle-loss-elderly-risk.json | 24 +++++++++++++++++++ ...arcopenia-glp1-muscle-loss-elderly-risk.md | 14 ++++++++++- 4 files changed, 49 insertions(+), 1 deletion(-) create mode 100644 inbox/archive/.extraction-debug/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.json diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index ff0765e39..98bd6459f 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -47,6 +47,12 @@ MASH/NASH is projected to become the leading cause of liver transplantation. GLP The BALANCE Model directly addresses the chronic use inflation problem by requiring lifestyle interventions alongside medication. If lifestyle supports can sustain metabolic benefits after medication discontinuation, the model could demonstrate a pathway to positive net cost impact. The 6-year test window (through 2031) will provide empirical data on whether combined intervention changes the chronic use economics. + +### Additional Evidence (challenge) +*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16* + +Sarcopenic obesity risk from muscle loss may create NEW healthcare costs that offset cardiovascular/metabolic savings. 15-40% of weight lost is lean mass, and with 64.8% discontinuation within 1 year, patients experience preferential fat regain without muscle recovery. In elderly populations (10-20% baseline sarcopenic obesity), this increases fall risk, fractures, and disability—potentially requiring MORE healthcare rather than less. The cost-savings thesis assumes net positive health effects, but if GLP-1s cause functional impairment in the Medicare-age population through sarcopenic disability, the arithmetic changes fundamentally. + --- Relevant Notes: diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 1f412e7f8..f851d69f0 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design. + +### Additional Evidence (extend) +*Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16* + +The high discontinuation rate creates a specific body composition trap: muscle lost during treatment is not regained after discontinuation, while fat returns preferentially. This means the 64.8% who discontinue within one year end up with worse body composition than baseline—more fat, less muscle, higher disability risk. The discontinuation problem is not just about losing metabolic benefits; it actively creates sarcopenic obesity through the weight cycling mechanism. + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.json b/inbox/archive/.extraction-debug/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.json new file mode 100644 index 000000000..9cc39a4c1 --- /dev/null +++ b/inbox/archive/.extraction-debug/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.json @@ -0,0 +1,24 @@ +{ + "rejected_claims": [ + { + "filename": "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 1, + "kept": 0, + "fixed": 1, + "rejected": 1, + "fixes_applied": [ + "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md:set_created:2026-03-16" + ], + "rejections": [ + "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-16" +} \ No newline at end of file diff --git a/inbox/archive/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.md b/inbox/archive/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.md index de9ecdae9..75f6e5816 100644 --- a/inbox/archive/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.md +++ b/inbox/archive/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.md @@ -7,9 +7,13 @@ date: 2025-07-01 domain: health secondary_domains: [] format: review -status: unprocessed +status: enrichment priority: medium tags: [glp-1, sarcopenia, muscle-loss, elderly, safety, lean-mass] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -50,3 +54,11 @@ WHY ARCHIVED: Counter-evidence to the GLP-1 benefit thesis — sarcopenia risk m EXTRACTION HINT: The intersection of muscle loss + high discontinuation rates is the key risk — evaluate as a challenge to the cost-savings thesis, not just a clinical side effect flagged_for_astra: ["GLP-1-induced muscle loss in elderly has parallels to spaceflight muscle atrophy — different mechanism but similar functional consequences"] + + +## Key Facts +- Natural aging reduces skeletal muscle mass by 12-16% +- Sarcopenic obesity prevalence in older adults: 10-20% +- 15-40% of total weight lost on GLP-1s is lean body mass, with some analyses suggesting up to 60% +- Next-generation GLP-1 compounds are being developed to improve muscle preservation +- ADA notes new therapies aim to 'enhance quality of weight loss by improving muscle preservation'